ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1810

Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)

Monica Schwartzman1, Zafir Abutalib2 and Lisa Mandl1, 1Hospital for Special Surgery, New York, NY, 2The Hospital For Special Surgery, New York, NY

Meeting: ACR Convergence 2021

Keywords: Clinical practice guidelines, Disease-Modifying Antirheumatic Drugs (Dmards), Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The advent of targeted synthetics and biologics has greatly broadened the options for effective treatment in PsA. Guidelines published in 2018 by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) support the use of biologic agents, including as initial therapy. Despite clear directives, there is a paucity of data regarding medication use in real world clinical practice and patient medication preferences.

Methods: This is a cross-sectional survey of Classification Criteria for Psoriatic Arthritis (CASPAR) criteria defined PsA patients recruited from a single academic center PsA registry from June-September 2020. Preferences were ranked on a 5-point Likert scale ranging from ‘not at all important’ to ‘extremely important.’

Results: One hundred thirty-seven(29%) PsA patients responded. Median age was 60 years (IQR 51-70). Median duration of PsA skin symptoms, joint symptoms and PsA diagnosis by a physician was 19 (IQR 10-34), 12 (IQR 8-21) and 8 (IQR 4-17) years, respectively.

Non-steroidal anti-inflammatory drugs were the first medication used for PsA in 62%. The most common initial immunomodulatory medications were anti-TNF-α (35%), followed by methotrexate (19%), anti-phosphodiesterase-4 (anti-PDE4) (12.4%), other conventional synthetic disease modifying anti-rheumatic medications (csDMARDs) (11.7%), anti-IL17 (5.1%), and anti-IL23 (2.9%). At survey administration, the most common immunomodulatory therapies were anti-TNF-α (30%), followed by anti-IL17 (20.4%), methotrexate (10.2%), anti-PDE4 (8.8%), other csDMARDs (8.0%), Janus kinase inhibitors (2.2%), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA 4) (1.5%), while 28% of patients were not on any immunomodulatory therapy. After 2018, when updated guidelines from the ACR/NPF were published, a significantly higher percentage of patients’ first medication was an anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001); a pattern also seen with anti-PDE4 (40% vs 11.5% p< 0.012).

Medication preferences most ranked as “extremely” important were prevention of joint damage, (80%), ability to perform daily activities (71%), prevention of pain (70%), rheumatologist recommendation (63%) and medication side effects (62%).

Conclusion: The significant increase of anti-IL17 and anti-PDE4 medications as initial treatment after 2018 may reflect their inclusion as potential initial therapy in updated guidelines, along with the importance placed by patients on medication side effects. Surprisingly, over a quarter of patients were not on any immunomodulatory therapy. Given the expanding armamentarium of PsA medications, it is increasingly important to align patient preferences and therapeutic options to ensure durable use of effective therapy.


Disclosures: M. Schwartzman, None; Z. Abutalib, None; L. Mandl, Regeneron Pharmaceuticals, 5.

To cite this abstract in AMA style:

Schwartzman M, Abutalib Z, Mandl L. Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/current-medication-practices-and-preferences-among-patients-with-psoriatic-arthritis-psa/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/current-medication-practices-and-preferences-among-patients-with-psoriatic-arthritis-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.